Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.

Abstract

We determined the long-term efficacy of intracavernous injection of a new formulation of prostaglandin E1 (Caverject) as treatment for erectile failure. A prospective study was done at a university affiliated Veterans Affairs medical center. Subjects with erectile failure received injections of prostaglandin E1 at the office and self-administered injections at home for up to 18 months. Of 16 patients who performed home injections 15 completed 6 months and 10 completed 18 months of therapy. Patient and spousal satisfaction with intercourse was 90% for months 1 to 6, and patient satisfaction was 95% for months 7 to 18. Prostaglandin E1 was highly effective at producing penile rigidity and an erection with satisfactory vaginal intercourse.